Standout Papers

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity... 2009 2026 2014 2020 832
  1. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies (2012)
    Ranjana H. Advani, Joseph J. Buggy et al. Journal of Clinical Oncology
  2. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia (2009)
    Jonathan W. Friedberg, Jeff P. Sharman et al. Blood

Immediate Impact

4 by Nobel laureates 37 from Science/Nature 77 standout
Sub-graph 1 of 20

Citing Papers

Targeting protein–ligand neosurfaces with a generalizable deep learning tool
2025 StandoutNature
Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
16 intermediate papers

Works of Jeff P. Sharman being referenced

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study
2019
Ublituximab ( TG ‐1101), a novel glycoengineered anti‐ CD 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
2016
and 7 more

Author Peers

Author Last Decade Papers Cites
Jeff P. Sharman 3803 3913 1854 240 5.9k
Eva Kimby 3939 4756 2770 201 7.6k
Kristie A. Blum 3806 4354 2512 206 6.5k
Richard Rosenquist 4187 3609 1521 250 7.5k
Sonali M. Smith 2274 4064 3254 262 6.6k
Francesc Bosch 4215 5469 3354 240 8.5k
Matthew S. Davids 3872 2951 1787 250 6.6k
Lorenz Trümper 2007 3812 3200 197 7.3k
Michinori Ogura 1774 3192 2918 221 7.2k
Alain Delmer 1831 2879 2142 194 5.1k
Lisa M. Rimsza 1516 3417 2577 198 6.0k

All Works

Loading papers...

Rankless by CCL
2026